GLP-1 weight management
Two SNPs predict how someone responds to incretin-receptor agonists. One is in GLP1R (rs10305420) and applies to every drug in the class. The other is in GIPR (rs1800437) and only matters for drugs that hit GIP, which means tirzepatide and retatrutide but not semaglutide. GIPR variant carriers tend to have more nausea on tirzepatide; switching to semaglutide often resolves it.
Gout
ABCG2 reduced-function carriers don't respond as well to allopurinol — they typically need higher doses to reach the under-6 mg/dL urate target, or a switch to febuxostat. The Q141K variant is common, particularly in East Asian populations, and is one of the more actionable pharmacogenetic signals outside psychiatry.
Three new DPWG antipsychotic guidelines
CYP2D6 and CYP3A4 phenotypes that change recommended dosing for haloperidol, quetiapine, and zuclopenthixol. Extrapyramidal side-effect risk is especially relevant for CYP2D6 poor metabolizers on haloperidol or zuclopenthixol.
Already a Gene2Rx subscriber?
Active subscribers automatically receive the v3 report at no extra cost. Sign in to view your updated results.